GCT President Takes Part in CTAD Congress

Dr. Jeffrey Apter is taking part in the CTAD Alzheimer’s congress. The event is being held November 9-12 at the Boston Park Plaza. It brings together key industry professionals and Key Opinion Leaders (KOLs) in Alzheimer’s disease to discuss the latest innovations and effective treatment development.

Currently, there are a few options available to mitigate the symptoms of the disease, but no cure has been invented yet. The research is ongoing and is especially active. Dr. Jeffrey Apter is a practicing psychiatrist and a Key Opinion Leader in Alzheimer’s disease with years of research experience and multiple publications on the topic. GCT has managed numerous Alzheimer’s trials both in the US and globally.

Please reach out to us at bd@gctrials.com to request more information.

Subscribe to our mailing list

Marketing Permissions

Please select all the ways you would like to hear from Global Clinical Trials (GCT):

You can unsubscribe at any time by clicking the link in the footer of our emails. Please see our Privacy Policy. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.


GCT is a CRO experienced in performing clinical research in the USA, Europe, Russia and India.

We are a full-service clinical development provider, offering feasibility analysis, regulatory submission, site selection, project management, monitoring, data management, logistics, and more.

Go social with us

Follow us on social networks:

Privacy policy, Terms of service, Site map, Employees login



© 2001—2021 Global Clinical Trials, LLC

All rights reserved.